高血压和 Lorundrostat:从TARGET-HTN试验的关键发现
Hamza Irfan1, Aliza Ahmed2, Komal Devi Nawani3
1Department of Cardiology, Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore, Lahore, Punjab, Pakistan.
Current problems in cardiology
|October 20, 2023
概括
目标-HTN试验表明,洛伦德洛斯塔特在具有特定激素特征的高血压患者中有效降低了缩血压. 建议对这种有前途的阿尔多氨酸合成酶抑制剂进行进一步的第三期试验.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压是一个全球性的健康问题,增加了心血管疾病 (CVD) 的风险和死亡率.
- 由于人口老龄化和生活方式因素,患病率正在上升,影响全球三分之一的成年人.
- 阿尔多斯特在血压调节中起着关键作用,使其抑制成为治疗目标.
研究的目的:
- 为了评估洛伦德罗斯塔特,阿尔多氨酸合成酶抑制剂,在降低缩血压的疗效.
- 评估洛伦德罗斯塔特在高血压患者的效果,特别是那些患有宁抑制和阿尔多激素升高的患者.
- 提供支持进入第三阶段临床试验的数据.
主要方法:
- 目标-HTN试验将高血压患者纳入两个队列.
- 第1组研究了每日50毫克和100毫克的洛伦德罗斯塔特剂量与安慰剂.
- 队列2在探索性分析中探索了每日100毫克的剂量.
主要成果:
- 洛伦德洛斯塔特 (每天100毫克和50毫克) 与安慰剂相比,在第1组中显著降低了系统血压.
- 在第2组中,每天服用100毫克lorundrostat的患者也观察到系统血压的显著降低.
- 这些结果表明lorundrostat在管理特定高血压患者亚组方面的潜力.
结论:
- 洛伦德洛斯塔特作为高血压的新疗法具有前景,特别是在血雷宁活性抑制和阿尔多激素升高的患者中.
- 阿尔多氨酸合成酶抑制剂为血压管理提供了一个新的治疗途径.
- 需要进行第三阶段试验,以证实lorundrostat在更广泛的人群中的安全性和有效性.
更多相关视频
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
752
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
752
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
15
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
15
01:29Hypertension II: Pathophysiology
14
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
14
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
12
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
12
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
177
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177